The future for tiotropium

Chest

Volumn 117, Issue 2 SUPPL., 2000, Pages 67S-69S

  Calverley, Peter M A ^a,b  

^a 5th Floor Duncan Building   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Anticholinergic agents; Bronchodilator therapy; COPD; Health related quality of life; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG FUNCTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SPIROMETRY; TREATMENT OUTCOME;

EID: 0033994342     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.2_suppl.67S     Document Type: Article

References (16)

1. Ferguson GT. Recommendations for the management of COPD. Chest 2000; 117(suppl):23S-28S
2. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society. Eur Respir J 1995; 8:1398-1420
3. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: ATS statement. Am J Respir Crit Care Med 1995; 152:S77-S121
4. Guidelines for the management of chronic obstructive pulmonary disease. Group of the Standards of Care Committee of the British Thoracic Society. Thorax 1997; 52:S1-S28
5. Pauwels RA. National and international guidelines for COPD: the need for evidence. Chest 2000; 117(suppl):20S-22S
6. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117(suppl):42S-47S
7. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000; 117(suppl): 54S-57S
8. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411-1419
9. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965
10. 1: the Lung Health Study. JAMA 1994; 272:1497-1505
11. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
12. Spencer S, Anie K, Calverley PMA, et al. Rate of health status decline is reduced in COPD patients treated with fluticasone compared to placebo [abstract]. Am J Respir Crit Care Med 1999; 159:A522
13. Friedman M, Serby CW, Menjoge SS, et al. Pharmacokinetic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635-641
14. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117(suppl):63S-66S
15. Casaburi R, Serby CW, Menjoge SS, et al. The spirometric efficacy of once daily dosing with tiotropium in stable COPD [abstract]. Am J Respir Crit Care Med 1999; 159:A524
16. Van Noord J, Bantje T, Eland M, et al. Superior efficacy of tiotropium compared to ipratropium as a maintenance treatment bronchodilator in COPD [abstract]. Am J Respir Crit Care Med 1999; 159:A525